Presence of Flavivirus Antibodies Does Not Lead to a Greater Number of Symptoms in a Small Cohort of Canadian Travelers Infected with Zika Virus.
Adult
Antibodies, Viral
/ blood
Canada
Case-Control Studies
Dengue Virus
/ immunology
Humans
Middle Aged
Real-Time Polymerase Chain Reaction
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Severity of Illness Index
Travel-Related Illness
Viremia
Zika Virus
/ isolation & purification
Zika Virus Infection
/ immunology
Zika virus
antibodies
clinical disease
dengue virus
viremia
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 Jan 2020
24 Jan 2020
Historique:
received:
25
10
2019
revised:
12
01
2020
accepted:
22
01
2020
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
20
3
2020
Statut:
epublish
Résumé
Zika virus (ZIKV) is a mosquito-borne flavivirus associated with a febrile illness as well as severe complications, including microcephaly and Guillain-Barré Syndrome. Antibody cross-reactivity between flaviviruses has been documented, and in regions where ZIKV is circulating, dengue virus (DENV) is also endemic, leaving the potential that previous exposure to DENV could alter clinical features of ZIKV infection. To investigate this, we performed a retrospective case-control study in which we compared Canadian travellers who had been infected with ZIKV and had serological findings indicating previous DENV or other flavivirus exposure (
Identifiants
pubmed: 31991674
pii: v12020140
doi: 10.3390/v12020140
pmc: PMC7077307
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Sci Rep. 2017 Sep 5;7(1):10498
pubmed: 28874759
J Clin Microbiol. 2016 Apr;54(4):860-7
pubmed: 26888897
N Engl J Med. 2016 Jul 21;375(3):294
pubmed: 27355411
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7852-7
pubmed: 27354515
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
Nat Commun. 2017 Jun 23;8:15674
pubmed: 28643775
J Clin Virol. 2016 Sep;82:1-4
pubmed: 27389909
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422757
J Clin Microbiol. 2017 May;55(5):1576-1584
pubmed: 28298448
JAMA Pediatr. 2018 Jul 1;172(7):686-693
pubmed: 29813148
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
Emerg Infect Dis. 2019 Aug;25(8):1485-1493
pubmed: 31075077
Clin Infect Dis. 2017 Oct 15;65(8):1260-1265
pubmed: 29017246
J Clin Invest. 2015 Dec;125(12):4421-8
pubmed: 26551677
J Gen Virol. 1989 Jan;70 ( Pt 1):37-43
pubmed: 2543738
Asian Pac J Trop Med. 2012 May;5(5):342-6
pubmed: 22546647
PLoS Pathog. 2017 Aug 3;13(8):e1006487
pubmed: 28771605
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
Sci Immunol. 2017 Aug 18;2(14):
pubmed: 28821561
MMWR Morb Mortal Wkly Rep. 2016 Jun 03;65(21):543-6
pubmed: 27254248
J Infect. 2017 Jun;74(6):611-615
pubmed: 28344113
West J Emerg Med. 2016 Nov;17(6):671-679
pubmed: 27833670
PLoS Negl Trop Dis. 2013 Aug 08;7(8):e2357
pubmed: 23951377
Bull World Health Organ. 2019 Jan 1;97(1):6-7
pubmed: 30618459
Nat Immunol. 2016 Sep;17(9):1102-8
pubmed: 27339099
J Infect Dev Ctries. 2016 Feb 28;10(2):116-20
pubmed: 26927450
J Infect Dis. 2016 Nov 1;214(9):1357-1360
pubmed: 27521359
Front Cell Infect Microbiol. 2018 Feb 15;8:44
pubmed: 29497604
Clin Infect Dis. 2017 Sep 15;65(6):877-883
pubmed: 28535184
J Clin Virol. 2017 Nov;96:20-25
pubmed: 28918127
Am J Trop Med Hyg. 2018 Sep;99(3):780-782
pubmed: 29943723
Science. 2017 Apr 14;356(6334):175-180
pubmed: 28360135
Open Forum Infect Dis. 2019 Jul 1;6(7):
pubmed: 31363765
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):521-34
pubmed: 12995441